WO2001078783A3 - Compositions comprising natural agents for treatment of cancer - Google Patents
Compositions comprising natural agents for treatment of cancer Download PDFInfo
- Publication number
- WO2001078783A3 WO2001078783A3 PCT/US2001/012096 US0112096W WO0178783A3 WO 2001078783 A3 WO2001078783 A3 WO 2001078783A3 US 0112096 W US0112096 W US 0112096W WO 0178783 A3 WO0178783 A3 WO 0178783A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- cancer
- natural agents
- treatment
- natural
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU5160201A AU5160201A (en) | 2000-04-17 | 2001-04-13 | Compositions comprising natural agents for treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55043600A | 2000-04-17 | 2000-04-17 | |
US09/550,436 | 2000-04-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001078783A2 WO2001078783A2 (en) | 2001-10-25 |
WO2001078783A3 true WO2001078783A3 (en) | 2002-07-04 |
Family
ID=24197183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/012096 WO2001078783A2 (en) | 2000-04-17 | 2001-04-13 | Compositions comprising natural agents for treatment of cancer |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5160201A (en) |
WO (1) | WO2001078783A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001256855A1 (en) * | 2000-05-08 | 2001-11-20 | N.V. Nutricia | Preparation for the prevention and treatment of ocular disorders |
AU2003217982A1 (en) * | 2002-03-06 | 2003-09-22 | The Medical Research And Education Trust | Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol |
AU2003257963B2 (en) * | 2002-08-01 | 2009-08-13 | Board Of Trustees Of The University Of Arkansas | Improved treatment of cancer with glutamine |
ITMI20022352A1 (en) * | 2002-11-06 | 2004-05-07 | Univ Catania | ANTI-CANCER PREPARATIONS CONTAINING RESVERATROL AND PROPOLIS. |
US8663679B2 (en) | 2004-04-29 | 2014-03-04 | Abbott Laboratories | Compositions for improving breast health in women |
ITFI20050031A1 (en) * | 2005-02-21 | 2006-08-22 | Stefan Coccoloni | A PHARMACEUTICAL COMPOSITION TO PREVENT THE AGING AND THE RISING OF VASCULAR, NEOPLASTIC, CUTANEOUS AND PILIFEROUS DISEASES |
US20080317885A1 (en) * | 2005-07-15 | 2008-12-25 | Baker Donald J | Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals |
US20080262081A1 (en) * | 2005-10-14 | 2008-10-23 | Daniel Raederstorff | Novel Use of Nutraceutical Compositions Comprising Resveratrol |
GB0800134D0 (en) * | 2008-01-04 | 2008-02-13 | Univ Nottingham | Ganoderma lucidum extracts for use in the treatment of cell neoplasia, cell proliferation and angiogenesis |
WO2010056318A2 (en) * | 2008-11-12 | 2010-05-20 | Andrew Loblaw | Nutritional supplement |
CN102309474B (en) * | 2010-07-02 | 2013-08-21 | 复旦大学 | Application of S-propargyl-cysteine in preparation of medicament for treating digestive system tumors |
EP2420289A1 (en) * | 2010-08-18 | 2012-02-22 | Grindeks, a joint stock company | Composition of caffeic acid phenethyl ester (CAPE) and one of catechin, kaempherol and myricetin for potentiating antitumour effect and for treating tumours |
US9040579B2 (en) * | 2010-10-18 | 2015-05-26 | Chemigen | Combination therapy using coenzyme Q10 and a caffeic acid-derived ester |
CN103127093B (en) * | 2011-12-02 | 2016-03-02 | 鲁南制药集团股份有限公司 | The purposes of arctigenin in preparation treatment or prevention cerebral glioma medicine |
CA2909349C (en) | 2013-04-12 | 2023-01-03 | Rebecca Lambert Bent | Use of a multi-agent composition for treatment of cancer |
ITMI20131495A1 (en) | 2013-09-10 | 2015-03-11 | Ce R C Ar Di Paolo Maestri | USEFUL COMPOSITIONS FOR CHEMOTHERAPY-RESISTANT CANCER TREATMENT |
CN104151392A (en) * | 2014-05-19 | 2014-11-19 | 浙江大学 | Moebioside A as well as preparation and application thereof |
WO2015193741A1 (en) * | 2014-06-20 | 2015-12-23 | Omni Cure Ltd. | Phyto-active based anti-cancer formulation |
BR112017000858A2 (en) | 2014-07-17 | 2017-12-05 | Probiotical Spa | compositions comprising melatonin and flavonoids for use in the treatment of chemotherapy resistant tumors |
CA2977910A1 (en) | 2015-03-05 | 2016-09-09 | Probiotical S.P.A. | Compositions for use in the treatment of tumors resistant to chemotherapy |
WO2016203392A1 (en) * | 2015-06-15 | 2016-12-22 | Gexnano S.R.L. | Food supplement for use in a process of metabolic rebalancing |
CN106389180B (en) * | 2015-07-29 | 2018-12-11 | 云南康恩贝植物研究院有限公司 | A kind of ginkgo procyanidine-polysaccharide mixed extract and its preparation method and application |
CN105147655A (en) * | 2015-09-07 | 2015-12-16 | 深圳市泰华细胞工程有限公司 | New purpose of SAMC (S-allylmercaptocysteine) |
WO2023014818A2 (en) * | 2021-08-03 | 2023-02-09 | Pebble Global Holdings | Non-psychoactive multi-cannabinoid and terpene-based therapeutic compositions and methods of their administration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2100669A1 (en) * | 1970-05-20 | 1972-03-24 | American General Entrepr | Ant-ageing lung-protecting compns |
WO2000070949A1 (en) * | 1999-05-20 | 2000-11-30 | Heng Madalene C Y | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases |
-
2001
- 2001-04-13 WO PCT/US2001/012096 patent/WO2001078783A2/en active Application Filing
- 2001-04-13 AU AU5160201A patent/AU5160201A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2100669A1 (en) * | 1970-05-20 | 1972-03-24 | American General Entrepr | Ant-ageing lung-protecting compns |
WO2000070949A1 (en) * | 1999-05-20 | 2000-11-30 | Heng Madalene C Y | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases |
Non-Patent Citations (1)
Title |
---|
M.G.L. HERTOG E.A.: "Intake and potentially anticarcinogenic flavonoids and their determinants in adults in the netherlands", NUTRITION AND CANCER, vol. 20, no. 1, 1993, pages 21 - 29, XP001073425 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001078783A2 (en) | 2001-10-25 |
AU5160201A (en) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001078783A3 (en) | Compositions comprising natural agents for treatment of cancer | |
WO2001012199A3 (en) | Methoxyamine potentiation of temozolomide anti-cancer activity | |
WO2005004818A3 (en) | Heterocyclic compounds and their use as anticancer agents | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
IL140710A0 (en) | Pulmonary delivery of active agents | |
WO2007011962A3 (en) | Treatment of cancer | |
AU2959595A (en) | Camptothecin drug combinations and medicaments with reduced side effects | |
EP1181013A4 (en) | Method and composition for the treatment of cancer | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
WO2005120461A3 (en) | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof | |
HUP0300798A3 (en) | Substituted-triazolopyrimidines and their use as anticancer agents and pharmaceutical compositions containing them | |
TW200519110A (en) | Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use | |
JO2373B1 (en) | W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | |
WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
TW200630343A (en) | 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof | |
WO2007062413A3 (en) | Use of parp-1 inhibitors | |
WO2003070283A3 (en) | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent | |
WO2002019981A3 (en) | Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use | |
BR0206046A (en) | Uses of a combination of protopanaxadiol sapogenin or protopanaxatriol sapogenin, and, pharmaceutical composition | |
IL150953A0 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
WO2002070464A3 (en) | Hydrazones and their therapeutic use | |
WO2002030941A3 (en) | Topoisomerase inhibitors | |
TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
EP1503748A4 (en) | Drugs for mitigating taxane-induced neurotoxicity | |
WO2003012051A8 (en) | Inhibitor of dna methylation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |